TABLE III.
Medical resources utilization (mru) costs per patient
| MRU | Cost a |
|---|---|
| Trastuzumab—adjuvant breast cancer | |
| Supportive medications | 1 |
| Diagnostic investigations | 1454 |
| Human resources | 1183 |
| Total | 2637 |
| Trastuzumab—metastatic breast cancer | |
| Supportive medications | 1 |
| Diagnostic investigations | 1175 |
| Human resources | 527 |
| Total | 1702 |
| Bevacizumab—metastatic colorectal cancer | |
| Supportive medications | 1 |
| Diagnostic investigations | 96 |
| Human resources | 1018 |
| Total | 1113 |
| Bevacizumab—metastatic NSCLC | |
| Supportive medications | 1 |
| Diagnostic investigations | 715 |
| Human resources | 524 |
| Total | 1239 |
a
In 2005 Canadian dollars.
nsclc = non-small-cell lung cancer.